Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE TranscriptSeeking Alpha • 8h
Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision NearsMarketBeat • Thursday
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026GlobeNewsWire • Thursday
Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in LondonGlobeNewsWire • Tuesday
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 11/06/26
Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in FocusZacks Investment Research • 11/06/26
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/05/26
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesGlobeNewsWire • 11/05/26
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)GlobeNewsWire • 11/04/26
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress PresentationsGlobeNewsWire • 11/03/26
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026GlobeNewsWire • 10/29/26
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowZacks Investment Research • 10/20/26
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/09/26
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?Zacks Investment Research • 09/18/26
Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE DrugZacks Investment Research • 09/09/26
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)GlobeNewsWire • 09/08/26
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 MillionGlobeNewsWire • 09/04/26
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewsWire • 09/04/26
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron RevenuesZacks Investment Research • 08/07/26